Format

Send to

Choose Destination
Vaccine. 2017 Mar 14;35(12):1590-1593. doi: 10.1016/j.vaccine.2017.02.007. Epub 2017 Feb 17.

Integrated analysis of recombinant BPV-1 L1 protein for the production of a bovine papillomavirus VLP vaccine.

Author information

1
Laboratório de Genética, Instituto Butantan, São Paulo, SP, Brazil.
2
Laboratório de Genética, Instituto Butantan, São Paulo, SP, Brazil; Programa de Pós-graduação Interunidades em Biotecnologia, Instituto de Ciências Biomédicas (ICB), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
3
Laboratório de Bioquímica e Biofísica, Instituto Butantan, São Paulo, SP, Brazil.
4
Laboratório Nacional de Ciência e Tecnologia do Bioetanol, Centro Nacional de Pesquisa em Energia e Materiais, Campinas, SP, Brazil.
5
Instituto de Biologia, Departamento de Genética, Evolução e Bioagentes, Universidade Estadual de Campinas, Campinas, SP, Brazil.
6
Laboratório de Genética, Instituto Butantan, São Paulo, SP, Brazil. Electronic address: rodsfc@uol.com.br.

Abstract

Bovine papillomatosis is an infectious disease that is caused by bovine papillomavirus (BPV), which results in important economic losses. However, no BPV vaccines or effective treatment methods are commercially available to date. Moreover, the absence of papillomavirus replication in vitro makes the use of recombinant protein a promising candidate for vaccine formulations. Hence, we developed an integrated study on the L1 capsid protein of BPV-1, obtained from a bacterial expression system, regarding its purification, biosafety, thermostability and immunogenicity. The results indicated an absence of genotoxicity of the purified recombinant L1 protein, β-sheet prevalence of secondary structure folding, protein stability under high temperatures as well as the presence of capsomeres and VLPs. In addition, preliminary experimental vaccination of calves showed the production of specific antibodies against BPV-1 L1.

KEYWORDS:

Biosafety; Bovine papillomavirus; Capsomeres; L1 protein; VLP; Vaccine

PMID:
28222997
DOI:
10.1016/j.vaccine.2017.02.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center